Objectives:
This study was conducted to assess the prevalence of Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV) among hemophilia and thalassemia patients.
Archives of Clinical Infectious Diseases
Infectious Diseases and Tropical Medicine Research Center, SBUMS
Authors
This study was conducted to assess the prevalence of Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV) among hemophilia and thalassemia patients.
Present study was conducted from October 2008 to December 2010 in Isfahan, Iran. One thousand one hundred and sixty adult multi-transfused patients (822 males, 338 females, mean age 22.711.5 years) suffering from beta-thalassemia (n = 545) and hemophilia (n=615) were enrolled in the study. Blood samples were obtained from the patients and were tested for HBs Ag, Anti-HCV Ag and Anti- HIV Ab. HCV positive patients underwent genotype determination.
Of 545 thalassemia patients, 312(57.2%) were male and 233 (42.8%) were female. From 615 hemophilia
patients, 511(83%) were male and 104 (17%) were female. Chronic hepatitis was detected in 505(82.1%) hemophilia patients of which 495 (98%) were HCV Ab positive and 10 (2%) had HBsAg positive. The prevalence of HCV Ab positive and HBsAg positive in 56 (11%) thalassemia patients with chronic hepatitis was 50 (89.2%) and 6 (10.8%) respectively. None of the thalassemia and hemophilia patients were positive for HIV Ab. History of hepatitis in family is the major risk factors and HCV genotype 1 was the major genotype in our patients.
HCV is the major virus of concern in multi-transfused patients. The strategies for prevention of HCV, HBV and HIV and safety of blood products in this respect have indeed been successful.
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Sayad B, Foroughikia M, Akramipour R, Farokhi A, Mansouri F, et al. Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection in Multi-Transfused Thalassemic Patients, Kermanshah, Iran, 2015. Jundishapur J Microbiol. 2017;10(5):e46152. doi: https://doi.org/10.5812/jjm.46152
Yousefi M, Dehesh MM, Ebadi M, Dehghan A. The Prevalence of Hepatitis C Virus Infection in Patients With Thalassemia in Zabol City of Iran. Int J Infect. 2017;4(1):e37009. doi: https://doi.org/10.17795/iji-37009
Abrishami F, Golshan A. The Prevalence of HBsAg, Anti-HCV, and Anti-HBc in Patients With β-Thalassemia Referred to Blood Banking Department of Ghaem Hospital in Mashhad, Northeast of Iran. Int J Infect. 2018;5(3):e81518. doi: https://doi.org/10.5812/iji.81518
Bozorgi H, Ramezani H, Vahid T, Mstajeri A, Kargarfard H, et al. The prevalence and risk factors of hepatitis C virus infection among thalassemic patients of Qazvin (2005). J Inflamm Dis. 2024;11(4):e155361. doi:
Karimi Elizee P, Alavian SM, Miri SM, Behnava B, Alavian SH, et al. The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran. Jundishapur J Microbiol. 2013;6(7):e9091. doi: https://doi.org/10.5812/jjm.9091
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 5 days ago
Last Update: 1 day ago
Last Update: 2 days ago